NIVF stock forecast, quote, news & analysis
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions... Show more
Why NewGenIvf Group (NIVF) Stock Is Down 91% in the Last 30 Days
Key Takeaways
- NIVF shares have fallen approximately 91% over the last 30 days, declining from about $2.88 per share to roughly $0.25 as of the latest completed trading session.
- The collapse was driven primarily by a deeply dilutive $1.25 million public offering priced at $0.07 per share for roughly 17.9 million shares in late September 2026.
- Repeated reverse stock splits, including a 1-for-4 split effective October 12, 2026, have been used to maintain Nasdaq listing compliance as the share price deteriorated.
- The company has pivoted from fertility services toward a diversified model spanning artificial intelligence, digital assets, and real estate, a transition the market has met with considerable skepticism.
- Over the last quarter the stock has shed roughly 98% of its value, reflecting persistent dilution, cash constraints, and weak investor confidence.
NewGenIvf Group (NIVF) Company Overview and Market Position
NewGenIvf Group Limited is a Bangkok-based holding company that began as a provider of assisted reproductive and fertility services, operating clinics across Thailand, Cambodia, Kyrgyzstan, and Hong Kong. Founded in 2010 and listed on the Nasdaq Capital Market through a business combination in April 2024, the company built a full suite of fertility offerings, including in vitro fertilization, embryo culture, chromosome screening, egg and sperm freezing, and surrogacy in the jurisdictions where it is permitted.
In recent periods, NewGen has repositioned itself as a "tech-forward, diversified" entity. Its stated strategy centers on licensing proprietary reproductive technologies while expanding into digital asset management — including a Solana treasury strategy and tokenization services — artificial intelligence through a stake in K25.ai, and real estate development through a joint venture in the UAE. Investors follow the stock for its small-cap, high-volatility profile and its attempt to transform into a technology- and blockchain-driven holding company, though the pivot has yet to restore durable market confidence.
NewGenIvf Group (NIVF) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NIVF has fallen roughly 91%. The shares traded near $2.88 per share about 30 days ago and closed near $0.25 in the most recent completed session, marking one of the steepest single-month declines in the stock's recent history.
The quarterly picture is even more pronounced. Approximately three months ago the stock traded near $15.72 per share, meaning the shares have declined roughly 98% over the last quarter. The move has been characterized by a persistent downward trend punctuated by sharp, high-volume sell-offs, particularly around late September, rather than a single gradual drift lower.
What Drove NIVF Stock Price in the Last 30 Days
The defining event of the recent 30-day move was a public offering. On September 28, 2026, the company priced a registered offering of 17,857,143 ordinary shares — or pre-funded warrants in lieu of shares — at $0.07 per share, generating gross proceeds of approximately $1.25 million with Aegis Capital Corp. acting as the exclusive placement agent. The pricing represented a steep discount to the then-market price and added a number of new shares that dwarfed the company's existing float, producing severe dilution for existing shareholders.
The company stated that net proceeds would be directed toward its investment in K25.ai, the restructuring of debt securities, working capital for manufacturing and deploying Nodexus cell-sorting machines, and general corporate purposes. The size and pricing of the raise signaled constrained access to capital, and the shares sold off sharply as the market repriced the expanded share count.
Compounding the pressure, the board approved a 1-for-4 reverse stock split effective October 12, 2026, reducing outstanding Class A ordinary shares from roughly 35.7 million to about 8.9 million. The split was aimed at lifting the share price back above Nasdaq's minimum bid-price requirements, but reverse splits do not change a company's underlying value and are frequently interpreted as a sign of financial stress.
What Drove NIVF Stock Performance Over the Last Quarter
Over the past quarter, the broader narrative has been one of a declining core business and an unproven strategic pivot. Fiscal 2025 results showed revenue of approximately $4.7 million, down from about $5.4 million a year earlier, while reported net income was supported largely by non-operating items such as cryptocurrency mark-to-market movements, a revaluation of the K25.ai stake, and bargain-purchase gains from acquisitions rather than cash generated by the fertility business.
The company has executed a series of reverse stock splits across 2025 and 2026 to remain listed on Nasdaq while continuing to issue new shares at progressively lower prices. This combination of shrinking share counts and expanding float has repeatedly eroded per-share value. The pivot into digital assets and AI has introduced additional volatility tied to cryptocurrency markets, and investors have remained cautious about the durability and cash-generating ability of these newer ventures.
Trending AI Robots
For traders seeking a more systematic approach to fast-moving small-cap and technology names, Tickeron's Trending AI Robots page offers a curated view of the platform's AI-powered trading bots. Tickeron provides hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore automated approaches aligned with different risk tolerances and holding periods. Whether you are interested in short-term momentum or longer-horizon signals, the page offers a neutral, data-driven starting point for evaluating algorithmic trading tools.
NIVF Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape NIVF's trajectory in the near term. First, Nasdaq listing compliance remains a key risk, and any further reverse splits or capital raises would affect the share count and per-share value. Second, the completion and valuation of the company's K25.ai investment, along with the commercialization of its Nodexus cell-sorting technology, will be closely watched as indicators of whether the pivot can generate sustainable revenue. Third, debt restructuring and working-capital needs may require additional financing, which could bring further dilution.
Investors should also monitor the stability of the legacy fertility business, which provides the company's core cash flows, as well as volatility in digital asset markets, given the company's cryptocurrency treasury strategy. Macroeconomic conditions, sector sentiment toward small-cap and speculative issuers, and regulatory developments affecting digital assets and assisted-reproduction services round out the key watch items. As always, these considerations are informational and should not be read as investment recommendations or predictions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NIVF's RSI Oscillator remains in oversold zone for 20 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for NIVF just turned positive on October 02, 2026. Looking at past instances where NIVF's MACD turned positive, the stock continued to rise in 8 of 11 cases over the following month. The odds of a continued upward trend are 73%.
Following a +13.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 67 of 80 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.017) is normal, around the industry mean (204.137). P/E Ratio (0.000) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement